Update on monoclonal antibody therapy in the gram-negative sepsis syndrome.
Two multicenter controlled clinical trials of genetically engineered monoclonal antibodies directed against endotoxin, a potent mediator of inflammation in the gram-negative sepsis syndrome, were recently reported in the medical literature. One of these antiendotoxin antibodies was derived from a murine (mouse) source, and the other antibody was derived mainly from a human source (nebacumab [negative bacteria human monoclonal antibody]). This article reviews recent literature concerning the use of these agents in the treatment of gram-negative sepsis syndrome. It also projects economic assessment data regarding the use of nebacumab in the United States.
Hecker
R B
RB
Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX 78234-6200.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016905:Gram-Negative Bacterial Infections / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007075:Immunoglobulin M / Q000276:immunology; D013577:Syndrome
D000911:Antibodies, Monoclonal; D007075:Immunoglobulin M